AZTR Stock Summary and Trading Ideas (Azitra | AMEX:AZTR)

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

Azitra trades on the AMEX stock market under the symbol AZTR.

As of September 8, 2026, AZTR stock price declined to $0.17 with 197,530 million shares trading.

AZTR has a beta of 0.94, meaning it tends to be less sensitive to market movements. AZTR has a correlation of 0.01 to the broad based SPY ETF.

AZTR has a market cap of $10.42 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, AZTR traded as high as $455.55 and as low as $.10.

AZTR has underperformed the market in the last year with a return of -80.5%, while the SPY ETF gained +19.2%. In the last 3 month period, AZTR fell short of the market, returning -21.1%, while SPY returned +1.4%. However, in the most recent 2 weeks AZTR has outperformed the stock market by returning +29.5%, while SPY returned 0.0%.

AZTR support price is $.17 and resistance is $.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AZTR shares will trade within this expected range on the day.